Health & WellnessTech
Women
TTC Oncology
TTC Oncology developed TTC-352, a small molecule to fight breast cancer.
Minneapolis,
MN
Investment type:
Equity
(SAFE)
Target raise:
$50,000
- $250,000
Minimum investment:
$100
$100
End date:
Jan 01, 2023
Jan 01, 2023
ended
Share
Highlights
- Novel mechanism of action therapy for hormone resistant of breast cancer.
- Intellectual property protected until 2033.
- Safe and well tolerated oral capsule therapy.
- Biomarker that identifies breast cancer that will respond well to TTC-352.
Our Story
We have developed new treatment for breast cancer.
Our Ambition
We would like to have our drug, TTC-352 available in pharmacies to help women with breast cancer.